effectively reduced. This causes COVID-19 to be greatly excessive, resulting in a cytokine catastrophe and vast tissue destruction [109]. In Peripheral blood mononuclear cells PBMCs and THP-1 cells (human monocyte cell line); G6PD insufficiency reduces IL-1b presentation and inhibits inflammasome reinvigoration in response to LPS and ATP/nigericin inducement [110].

Reduced ROS generation through NOX is answerable for the reduced inflammasome activation; contrastingly H_2O_2 promotes inflammasome insinuation in G6PD-knockdown THP-1 cells. In G6PD-knockdown THP-1 cells, this comes out to reduce bactericidal action towards Staph. Aureus and E. coli, pointing that G6PD enzyme is necessary for the upkeep of the innate immunological response, inflammasome induction, and pathogen removal *via* redox equilibrium. [110]

Interplay of G6PD insufficiency and SARS-COV-2

SARS-COV-2 virulence in humans is affected by hereditary types of G6PD that are linked to an incapacitated immunological reaction [111]. COVID-19 is expected to spread more broadly in places or countries where the frequency of G6PD deficiency is high. This issue makes treating COVID-19 in G6PD-insufficient individuals difficult. G6PD insufficiency is linked to a changed immunological response, which includes NET synthesis, inflammasome exhilaration, bactericidal action, and antiviral activity [9–11,42,85,95,110]. As a result, G6PD deficiency is an issue during the COVID-19 pandemic. The clinical virulence of COVID-19 patients can be affected by factors. In COVID-19 patients, age is linked to increased morbidity and mortality [112]. When compared to middle-aged patients and the young, the elderly in accordance to COVID-19 (32%) had greater mortality rates [113]. The elderly with concomitant diseases including diabetes, hypertension, and obesity have a five-fold increased mortality risk [114]. During COVID-19 infection, oxidative damage and ageing go hand in hand. Aging has an impact on the immune system, as well as causing a pro-inflammatory condition. Infected older animals have more exasperating lesions and higher pro-inflammatory response in comparison to their younger counterparts [115] suggesting that as people become older, they accumulate more oxidative stress and have a worse anti oxidative defence, which might make viral infections worse [116]. G6PD-deficient mutations are thought to make COVID-19 more severe clinically. As a result, people with G6PD deficiency may turn over to being more anaemic in old age with COVID-19 than those with normal G6PD activity [117,118].

Ethnicity is a major contributing risk factor adhered to a greater prevalence of COVID-19 infection. COVID-19 is more common among African-Americans [119]. In comparison to G6PD-normal African Americans, G6PD-insufficient American-Africans had greater blood levels of GSSG with lipid peroxide [120]. Tocopherol and L-cysteine molecule co-supplementation is explained for counselling for enhanced oxidation tensity with a debillated immunological response in G6PD-deficient African-Americans infected with SARS-CoV-2 [121].

Prospective impact on COVID-19 treatment modalities by G6PD insufficiency

Malaria and amoebic infections are customarily treated with Chloroquine (CQ) and 4 amino quinolone drugs [122,123]. Because of its ability to measure irritability and immune response, it is used to treat auto immunological diseases such as lupus erythematosus and rheumatoid arthritis [124,125]. CQ has an unsaid effect on some viruses. CQ produces an affirmative response to fungal infections, HIV and HCV [126-129]. Yet it does not work in flu and dengue [126,130]. Hydroxychloroquine is a turnaround for chloroquine currently being tested in COVID-19 scientific research [131]. In some places, the possible apprehension of Hydroxychloroquine averse to COVID-19 may also lift up wellbeing concerns [132]. CQ or HCQ may be connected with haemolysis in the absence of G6PD, according to recent findings [133-135]. However, no case of haemolysis was detected after HCQ treatment in patients without G6PD in two large retrospective studies [136,137]. As a result, the hypothesis that chloroquine exposure causes oxidative haemolysis in people deficient in G6PD has not been established [138].

DISCUSSION

In addition to attempts in producing COVID-19 vaccines, studies show that adults do not fully acknowledge how the immune system works. The body's response to encroaching viruses is weakened by the loss of T and B cells as people grow in age. In addition, inflammation, or persistent infection, results in a decrease in the ability to respond to external stimuli. Those events weaken the immune system and decrease the immune response to vaccines [139]. However, specific anti-ageing drugs promise in parts that enhance the anti-bacterial response of the elderly population.

In the old age population, the mTOR inhibitor decreases contamination, complements vaccination counteractions, and improves antiviral response [140]. Metformin is a well-known drug for diabetes that improves longevity in mice by blocking mTOR in a circular manner [141]. Patients treated with COVID-19 taking metformin have a lower mortality rate [142,143]. During aging, senolytic drugs decrease flare up and pull out senescent cell chambers selectively [144]. Those anti-aging products may promote energy that helps to reduce redox imbalance and decreases oxidant stress [145-147].

Those compounds, when combined in association with COVID-19, can decrease mortality, adhere to the treatment of the elderly etc. [148-151]. This enhances the use of therapeutic drugs for example calorie restriction mimetics and/or senolytics prior to vaccination to reduce the symptoms of aging or immune deficiency in adults [152]. These drugs can also assist adults with G6PD deficiency with the help of improving their anti-oxidative and immunological safeguards and vindications.

CONCLUSION

A courting among G6PD insufficiency, most frequent enzymopathy, and COVID-19, a terrifying pandemic, has been proven inside the current mini-review. The premise for this connection is redox homeostasis. Many cell immune responses are tormented by G6PD loss, together with extended manufacturing of the seasoned-inflammatory chemokine IL-8 with reduced inflammasome action. Some viral infestations are also linked to something called a G6PD insufficiency. G6PD insufficiency has exacerbated the virulence of COVID-19 contamination at some point of the cutting-edge pandemic. G6PD deficiency causes irregularities in redox homeostasis, which might be related to altered redox homeostasis. Alternative drugs, consisting of nutrition C, vitamin D, and NAC, in addition to positive present anti-getting old prescription drugs, appear encouraging for treatment of COVID-19 with vaccination.

DISCLOSURE STATEMENT

No potential conflict of interest was reported by the author(s).

REFERENCES

1. World Health Organization. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update 2020.
2. Tal S, Spectre G, Kornowski R, et al. Venous thromboembolism complicated with COVID-19: what do we know so far? Acta haematologica. 2020; 143:417-424.
3. Beltrán-García J, Osca-Verdegal R, Pallardó FV, et al. Oxidative stress and inflammation in COVID-19-associated sepsis: the potential role of anti-oxidant therapy in avoiding disease progression. Antioxidants 2020; 9:936.
4. Iwasaki M, Saito J, Zhao H, et al. Inflammation triggered by SARS-CoV-2 and ACE2 augment drives multiple organ failure of severe COVID-19: molecular mechanisms and implications. Inflammation 2021; 44:13-34.
5. de la Rica R, Borges M, Gonzalez-Freire M. COVID-19: in the eye of the cytokine storm. Front Immunol 2020: 2313.
6. Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Resp Med 2020; 8:1233-1244.
7. de Virgiliis F, Di Giovanni S. Lung innervation in the eye of a cytokine storm: neuroimmune interactions and COVID-19. Nat Rev Neurol 2020; 16:645-652.
8. Kellner M, Noonepalle S, Lu Q, et al. ROS signaling in the pathogenesis of Acute Lung Injury (ALI) and acute respiratory distress syndrome. Adv Exp Med Biol 2017; 105-137.
9. Wu YH, Tseng CP, Cheng ML, et al. Glucose-6-phosphate dehydrogenase deficiency enhances human coronavirus 229E infection. J Infect Dis 2008; 197:812-816.
10. Wu YH, Chiu DT, Lin HR, et al. Glucose-6-phosphate dehydrogenase enhances antiviral response through downregulation of NADPH sensor HSCARG and upregulation of NF-κB signaling. Viruses 2015; 7:6689-6706.
11. Lin HR, Wu YH, Yen WC, et al. Diminished COX-2/PGE2-mediated antiviral response due to impaired NOX/MAPK signalling in G6PD-knockdown lung epithelial cells. PLoS One 2016; 11:0153462.
12. Bahammam AS, Bindayna KM, Joji RM, et al. Outcomes of COVID-19 in the Eastern Mediterranean Region in the first 4 months of the pandemic. Saudi Med J 2020; 41:907-915.
13. Iftimie S, López-Azcona AF, Vicente-Miralles M, et al. Risk factors associated with mortality in hospitalized patients with SARS-CoV-2 infection. A prospective, longitudinal, unicenter study in Reus, Spain. PloS one 2020; 15:e0234452.
14. Jamerson BD, Haryadi TH, Bohannon A. Glucose-6-phosphate dehydrogenase deficiency: an actionable risk factor for patients with COVID-19?. Arch Med Res 2020; 51:743-744.
15. Wu YH, Lee YH, Shih HY, et al. Glucose-6-phosphate dehydrogenase is indispensable in embryonic development by modulation of epithelial-mesenchymal transition via the NOX/Smad3/miR-200b axis. Cell Death Dis 2018; 9:10. \
16. Yang HC, Yu H, Liu YC, et al. IDH-1 deficiency induces growth defects and metabolic alterations in GSPD-1-deficient Caenorhabditis elegans. J Mol Med 2019; 97:385-396.
17. Yang HC, Cheng ML, Ho HY, et al. The microbicidal and cytoregulatory roles of NADPH oxidases. Microbes Infect 2011; 13:109–120.
18. Davies KJ. The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress. IUBMB Life 1999; 48:41–47.
19. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 1995; 18:775–794.
20. Liochev SI. Reactive oxygen species and the free radical theory of aging. Free Radic Biol Med 2013; 60:1-4.
21. Vina J, Borras C, Abdelaziz KM, et al. The free radical theory of aging revisited: the cell signalling disruption theory of aging. Antioxid Redox Signal 2013; 19:779–787.
22. Beutler E. G6PD deficiency. Blood 1994; 84:3613–3636.
23. Gomez-Manzo S, Marcial-Quino J, Vanoye-Carlo A, et al. Glucose-6-phosphate dehydrogenase: update and analysis of new mutations around the world. Int J Mol Sci 2016; 17:2069.

24. La Vieille S, Lefebvre DE, Khalid AF, et al. Dietary restrictions for people with glucose-6-phosphate dehydrogenase deficiency. Nutr Rev 2019; 77:96–106.
25. Abdel Hakeem GL, Abdel Naeem EA, Swelam SH, et al. Detection of occult acute kidney injury in glucose-6-phosphate dehydrogenase deficiency anemia. Mediterr J Hematol Infect Dis 2016; 8:e2016038.
26. Mason PJ, Bautista JM, Gilsanz F. G6PD deficiency: the genotype-phenotype association. Blood Rev 2007; 21:267–283.
27. Ho HY, Cheng ML, Lu FJ, et al. Enhanced oxidative stress and accelerated cellular senescence in Glu-cose-6-Phosphate Dehydrogenase (G6PD)-deficient human fibroblasts. Free Radic Biol Med 2000; 29:156-169.
28. Yang HC, Wu YH, Yen WC, et al. The redox role of G6PD in cell growth Cell Death, and Cancer. Cells 2019; 8:1055.
29. Cheng ML, Ho HY, Liang CM, et al. Cellular Glucose-6-Phosphate Dehydrogenase (G6PD) status modu-lates the effects of Nitric Oxide (NO) on human fore-skin fibroblasts. FEBS Lett 2000; 475:257-262.
30. Gao LP, Cheng ML, Chou HJ, et al. Ineffective GSH regeneration enhances G6PD-knockdown HepG2 cell sensitivity to diamide-induced oxidative damage. Free Radic Biol Med 2009; 47:529–535.
31. Lin CJ, Ho HY, Cheng ML, et al. Impaired dephos-phorylation renders G6PD-knockdown HepG2 cells more susceptible to H2O2 induced apoptosis. Free Radic Biol Med 2010; 49:361–373.
32. Zekavat OR, Makarem A, Bahrami R, et al. Relationship of glucose-6-phosphate dehydrogenase deficiency and neonatal sepsis: a single-center inves-tigation on the major cause of neonatal morbidity and mortality. Pediatric Health Med Ther 2019; 10:33–37.
33. Rostami-Far Z, Ghadiri K, Rostami-FarM, et al. Glucose-6-Phosphate Dehydrogenase Deficiency (G6PD) as a risk factor of male neonatal sepsis. J Med Life 2016; 9:34–38.
34. Christensen RD, Yaish HM, Wiedmeier SE, et al. Neonatal death suspected to be from sepsis was found to be kernicterus with G6PD deficiency. Pediatrics 2013; 132:1694–1698.
35. Liao SL, Lai SH, Tsai MH, et al. Cytokine responses of TNF-a, IL-6, and IL-10 in G6PD-deficient infants. Pediatr Hematol Oncol. 2014; 31:87–94.
36. Wilmanski J, Siddiqi M, Deitch EA, et al. Augmented IL-10 production and redox-dependent signaling pathways in glucose-6-phosphate dehydrogenase-deficient mouse peritoneal macrophages. J Leukoc Biol 2005; 78:85–94.
37. Liese AM, Siddiqi MQ, Siegel JH, et al. Attenuated monocyte IL-10 production in glucose-6-phosphate dehydrogenase-deficient trauma patients. Shock 2002; 18:18–23.
38. Peiro C, Romacho T, Azcutia V, et al. Inflammation, glucose, and vascular cell damage: the role of the pentose phosphate pathway. Cardiovasc Diabetol 2016; 15:82.
39. Yang HC, Cheng ML, Hua YS, et al. Glucose 6-phosphate dehydrogenase knockdown enhances IL-8 expression in HepG2 cells via oxidative stress and NF-jB signaling pathway. J Inflamm (Lond) 2015; 12:34.
40. Sanna F, Bonatesta RR, Frongia B, et al. Production of inflammatory molecules in peripheral blood mono-nuclear cells from severely glucose-6-phosphate dehydrogenase-deficient subjects. J Vasc Res 2007; 44:253–263.
41. van Bruggen R, Bautista JM, Petropoulou T, et al. Deletion of leucine 61 in glucose-6-phosphate dehydrogenase leads to chronic nonspherocytic anemia, granulocyte dysfunction, and increased sus-ceptibility to infections. Blood 2002; 100:1026–1030.
42. Tsai KJ, Hung IJ, Chow CK, et al. Impaired production of nitric oxide, superoxide, and hydrogen peroxide in glucose 6-phosphate-dehydrogenase-deficient granu-locytes. FEBS Lett 1998; 436:411–414.
43. Ham M, Lee JW, Choi AH, et al. Macrophage glucose-6-phosphate dehydrogenase stimulates proinflamma-tory responses with oxidative stress. Mol Cell Biol 2013; 33:2425–2435.
44. Chen KK, Minakuchi M, Wuputra K, et al. Redox control in the pathophysiology of influenza virus infection. BMC Microbiol 2020; 20:214.
45. Colado Simao AN, Victorino VJ, Morimoto HK, et al. Redox-driven events in the human immunodeficiency virus type 1 (HIV-1) infection and their clinical implications. Curr HIV Res 2015; 13:143–150.
46. Garofalo RP, Kolli D, Casola A. Respiratory syncytial virus infection: mechanisms of redox control and novel therapeutic opportunities. Antioxid Redox Signal 2013; 18:186–217.
47. Baker DH, Wood RJ. Cellular antioxidant status and human immunodeficiency virus replication. Nutr Rev 1992; 50:15–18.
48. Louboutin JP, Strayer D. Role of oxidative stress in HIV-1-associated neurocognitive disorder and protec-tion by gene delivery of antioxidant enzymes. Antioxidants Basel 2014; 3:770–797.
49. Soto ME, Guarner-Lans V, Soria-Castro E, et al. Is antioxidant therapy a useful complementary measure for Covid-19 treatment? An algorithm for its applica tion. Medicina (Kaunas) 2020; 56:386.
50. Uchide N, Toyoda H. Antioxidant therapy as a potential approach to severe influenza-associated complications. Molecules 2011; 16:2032–2052.

51. Staal FJ, Ela SW. Glutathione deficiency and human immunodeficiency virus infection. Lancet. 1992; 339:909-912.
52. Verma S, Molina Y, Lo YY, et al. *In vitro effects of selenium deficiency on West Nile virus replication and cytopathogenicity*. Virol J. 2008; 5:1-3.
53. Aubry M, Laughhunn A, Santa Maria F, et al. Pathogen inactivation of Dengue virus in red blood cells using amustaline and glutathione. Transfus 2017; 57:2888-2896.
54. Laughhunn A, Huang YJ, Vanlandingham DL, et al. Inactivation of chikungunya virus in blood components treated with amotosalen/ultraviolet A light or amustaline/glutathione. Transfus 2018; 58:748-757.
55. Ibrahim H, Perl A, Smith D, et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. J Clin Immunol 2020; 219:108544.
56. Beck MA, Kolbeck PC, Rohr LH, et al. Benign human enterovirus becomes virulent in selenium-deficient mice. J Med Virol 1994; 43:166-170.
57. Beck MA, Kolbeck PC, Shi Q, et al. Increased virulence of a human enterovirus (coxsackievirus B3) in seleniumdeficient mice. J Infect Dis 1994; 170:351-357.
58. Herzenberg LA, De Rosa SC, Dubs JG, et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci USA 1997; 94:1967-1972.
59. Pauling L. Vitamin C and common cold. Jama 1971; 216:332.
60. Pullar JM, Carr AC, Vissers M. The roles of vitamin C in skin health. Nutrients 2017; 9:866.
61. Ang A, Pullar JM, Currie MJ, et al. Vitamin C and immune cell function in inflammation and cancer. Biochem Soc Trans 2018; 46:1147-1159.
62. Vissers M, Das AB. Potential mechanisms of action for vitamin C in cancer: reviewing the evidence. Front Physiol 2018; 809.
63. Wohlrab C, Kuiper C, Vissers MC, et al. Ascorbate modulates the hypoxic pathway by increasing intracellular activity of the HIF hydroxylases in renal cell carcinoma cells. Hypoxia 2019; 7:17.
64. Ponec M, Weerheim A, Kempenaar J, et al. The formation of competent barrier lipids in reconstructed human epidermis requires the presence of vitamin C. J Invest Dermatol 1997; 109:348-355.
65. Mohammed BM, Fisher BJ, Kraskauskas D, et al. Vitamin C promotes wound healing through novel pleiotropic mechanisms. Int Wound J 2016; 13:572-584.
66. Johnston CS, Huang S. Effect of ascorbic acid nutriture on blood histamine and neutrophil chemotaxis in guinea pigs. J Nutr 1991; 121:126-130.
67. Goldschmidt MC, Masin WJ, Brown LR, et al. The effect of ascorbic acid deficiency on leukocyte phagocytosis and killing of actinomyces viscosus. Int J Vitam Nutr Res 1988; 58:326-334.
68. Vissers MC, Wilkie RP. Ascorbate deficiency results in impaired neutrophil apoptosis and clearance and is associated with up-regulation of hypoxia-inducible factor 1α. J Leukoc Biol 2007; 81:1236-1244.
69. Mohammed BM, Fisher BJ, Kraskauskas D, et al. Vitamin C: a novel regulator of neutrophil extracellular trap formation. Nutrients 2013; 5:3131-3150.
70. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008; 7:156-167.
71. Ran L, Zhao W, Wang J, et al. Extra dose of vitamin C based on a daily supplementation shortens the common cold: A meta-analysis of 9 randomized controlled trials. BioMed Res Int 2018.
72. Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition 2020; 12:100190.
73. Corpe CP, Eck P, Wang J, et al. Intestinal Dehydroascorbic Acid (DHA) transport mediated by the facilitative sugar transporters, GLUT2 and GLUT8. J Biol Chem 2013; 288:9092-9101.
74. Baladia E, Pizarro AB, Ortiz-Muñoz L, et al. Vitamin C for COVID-19: A living systematic review. Medwave 2020; 20.
75. Caruso AA, Del Prete A, Lazzarino AI. Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic. Med Hypotheses 2020; 144:109910.
76. Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020; 104:246-251.
77. Yamasaki H. Blood nitrate and nitrite modulating nitric oxide bioavailability: Potential therapeutic functions in COVID-19. Nitric Oxide 2020; 103:29-30.
78. Ignarro LJ. Inhaled NO and COVID-19. Br J Pharmacol 2020; 177:3848-3849.
79. Sobko T, Marcus C, Govoni M, et al. Dietary nitrate in Japanese traditional foods lowers diastolic blood pressure in healthy volunteers. Nitric Oxide 2010; 22:136-140.
80. Guo L, Zhang Z, Green K, et al. Suppression of interleukin-1β-induced nitric oxide production in RINm5F cells by inhibition of glucose-6-phosphate dehydrogenase. Biochemistry 2002; 41:14726-14733.
81. Leopold JA, Cap A, Scribner AW, et al. Glucose-6-phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases

endothelial nitric oxide bioavailability. FASEB J 2001; 15:1771-1773.

82. Parsanathan R, Jain SK. Glucose-6-phosphate dehydrogenase deficiency increases cell adhesion molecules and activates human monocyte-endothelial cell adhesion: Protective role of l-cysteine. Arch Biochem Biophys 2019; 663:11-21.
83. García-Nogales P, Almeida A, et al. Peroxynitrite protects neurons against nitric oxide-mediated apoptosis: a key role for glucose-6-phosphate dehydrogenase activity in neuroprotection. J Biol Chem 2003; 278:864-774.
84. Ho HY, Cheng ML, Weng SF, et al. Glucose-6-phosphate dehydrogenase deficiency enhances enterovirus 71 infection. J Gen Virol 2008; 89:2080-2089.
85. Chao YC, Huang CS, Lee CN, et al. Higher infection of dengue virus serotype 2 in human monocytes of patients with G6PD deficiency. PLoS One 2008; 3:1557.
86. Naumenko V, Turk M, Jenne CN, et al. Neutrophils in viral infection. Cell Tissue Res 2018; 371:505-516.
87. Barr FD, Ochsenbauer C, Wira CR, et al. Neutrophil extracellular traps prevent HIV infection in the female genital tract. Mucosal Immunol 2018; 11:1420-1428.
88. Hiroki CH, Toller-Kawahisa JE, Fumagalli MJ, et al. Neutrophil extracellular traps effectively control acute chikungunya virus infection. Front Immunol 2020; 10:3108.
89. Sivanandham R, Brocca-Cofano E, Krampe N, et al. Neutrophil extracellular trap production contributes to pathogenesis in SIV-infected nonhuman primates. J. Clin Investig 2018; 128:5178-5183.
90. Souza PS, Barbosa LV, Diniz LF, et al. Neutrophil extracellular traps possess anti-human respiratory syncytial virus activity: Possible interaction with the viral F protein. Virus Res 2018; 251:68-77.
91. Twaddell SH, Baines KJ, Grainge C, et al. The emerging role of neutrophil extracellular traps in respiratory disease. Chest 2019; 156:774-782.
92. Azevedo EP, Rochael NC, Guimaraes-Costa AB, et al. A metabolic shift toward pentose phosphate pathway is necessary for amyloid fibril-and phorbol 12-myristate 13-acetate-induced Neutrophil Extracellular Trap (NET) formation. J Biol Chem 2015; 290:22174-22183.
93. Cheng ML, Ho HY, Lin HY, et al. Effective NET formation in neutrophils from individuals with G6PD Taiwan-Hakka is associated with enhanced NADP+ biosynthesis. Free Radic Res 2013; 47:699-709.
94. Siler U, Romao S, Tejera E, et al. Severe glucose-6-phosphate dehydrogenase deficiency leads to susceptibility to infection and absent NETosis. J Allergy Clin Immunol Pract 2017; 139:212-219.
95. Veras FP, Pontelli MC, Silva CM, et al. SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology. J Exp Med 2020; 217.
96. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Experiment Med 2020; 217.
97. Hidalgo A. A NET-thrombosis axis in COVID-19. Blood 2020; 136:1118-1119.
98. Makatsariya A, Slukhanchuk E, Bitsadze V, et al. COVID-19, neutrophil extracellular traps and vascular complications in obstetric practice. J Perinat Med 2020; 48:985-994.
99. Middleton EA, He XY, Denorme F, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 2020; 136:1169-1179.
100. Schonrich G, Raftery MJ, Samstag Y, et al. Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. Adv Biol Regul 2020; 77:100741.
101. Thierry AR, Roch B. Neutrophil extracellular traps and by-products play a key role in COVID-19: pathogenesis, risk factors, and therapy. J Clin Med 2020; 9:2942.
102. Yaqinuddin A, Kashir J. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1b/neutrophil extracellular traps feed-back loop. Med Hypotheses 2020; 143:109906.
103. Antushevich H. Interplays between inflammasomes and viruses, bacteria (pathogenic and probiotic), yeasts and parasites. Immunol Lett 2020; 228:1-14.
104. Zhao C, Zhao W. NLRP3 inflammasome-A key player in antiviral responses. Front Immunol 2020; 11:211.
105. Zheng M, Williams EP, Malireddi RKS, et al. Impaired NLRP3 inflammasome activation/pyroptosis leads to robust inflammatory cell death via caspase-8/RIPK3 during coronavirus infection. J Biol Chem 2020; 295:14040-14052.
106. Samir P, Malireddi RKS, Kanneganti TD, et al. The PANoptosome: a deadly protein complex driving pyroptosis, apoptosis, and necroptosis (PANoptosis). Front Cell Infect Microbiol 2020; 10:238.
107. Ratajczak MZ, Kucia M. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hem-atopoietic stem cells. Leukemia 2020; 34:1726-1729.
108. van den Berg DF, Te Velde AA. Severe COVID. NLRP3 Inflammasome Dysregulated. Front Immunol 2020; 1911:1580.
109. Yen WC, Wu YH, Wu CC, et al. Impaired inflammasome activation and bacterial clearance in G6PD

deficiency due to defective NOX/p38 MAPK/AP-1 redox signaling. Redox Biol 2020; 28:101363.

110. Elhabyan A, Elyaacoub S, Sanad E, et al. The role of host genetics in susceptibility to severe viral infec-tions in humans and insights into host genetics of severe COVID-19: A systematic review. Virus Res 2020; 289:198163.
111. Fauci AS, Lane HC, Redfield RR, et al. COVID-19-navigating the uncharted. N Engl J Med 2020; 382:1268-1269.
112. Liu K, Chen Y, Lin R, et al. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect 2020; 80:14-18.
113. Jordan RE, Adab P, Cheng KK, et al. COVID-19: risk factors for severe disease and death. BMJ 2020; 368:1198.
114. Rockx B, Baas T, Zornetzer GA, et al. Early upregulation of acute respiratory distress syndrome-associ-ated cytokines promotes lethal disease in an agedmouse model of severe acute respiratory syndrome coronavirus infection. J Virol 2009; 83:7062-7074.
115. Delgado-Roche L, Mesta F. Oxidative stress as key player in severe acute respiratory syndrome corona-virus (SARS-CoV) infection. Arch Med Res 2020; 51:384-387.
116. Lupescu A, Bissinger R, Goebel T, et al. Enhanced sui-cidal erythrocyte death contributing to anemia in the elderly. Cell Physiol Biochem 2015; 36:773-783.
117. Aydemir D, Ulusu NN. Is glucose-6-phosphate dehydrogenase enzyme deficiency a factor in Coronavirus-19 (COVID-19) infections and deaths? Pathog Glob Health 2020; 114:109-110.
118. Andrasfay T, Goldman N. Reductions in 2020US life expectancy due to COVID-19 and the disproportionate impact on the Black and Latino populations. medRxiv 2020.
119. Jain SK, Palmer M. Effect of glucose-6-phosphate dehydrogenase deficiency on reduced and oxidized glutathione and lipid peroxide levels in the blood of African-Americans. Clin Chim Acta 1996; 253:181-183.
120. Jain SK, Parsanathan R, Levine SN, et al. The potential link between inherited G6PD deficiency, oxidative stress, and vitamin D deficiency and the racial inequities in mortality associated with COVID-19. Free Radic Biol Med 2020; 161:84-91.
121. Zulfiqar H, Mathew G, Horrall S, et al. Amebiasis. Treasure Island (FL): StatPearls 2020.
122. Pillat MM, Kruger A, Guimaraes LMF, et al. Insights in chloroquine action: perspectives and implications in malaria and COVID-19. Cytometry A 2020; 97:872-881.
123. Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol 2011; 23:278-281.
124. Connolly KM, Stecher VJ, Danis E, et al. Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease modifying antirheumatic drugs. Agents Actions 1988; 25:94-105.
125. Tricou V, Minh NN, Van TP, et al. A randomized controlled trial of chloroquine for the treatment of den-gue in Vietnamese adults. PLoS Negl Trop Dis 2010; 4:785.
126. Roques P, Thiberville SD, Dupuis-Maguiraga L, et al. Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses 2018; 10:268.
127. Maheshwari RK, Srikantan V, Bhartiya D, et al. Chloroquine enhances replication of Semliki Forest virus and encephalomyocarditis virus in mice. J Virol 1991; 65:992-995.
128. Chauhan A, Tikoo A. The enigma of the clandestine association between chloroquine and HIV-1 infection. HIV Med 2015; 16:585-590.
129. Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis 2011; 11:677-683.
130. Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res 2020; 177:104762.
131. Kassi EN, Papavassiliou KA, Papavassiliou AG, et al. G6PD and chloroquine: Selecting the treatment against SARS-CoV-2. J Cell Mol Med 2020; 24:4913-4914.
132. Kuipers MT, van Zwieten R, Heijmans J, et al. Glucose-6-phosphate dehydrogenase deficiency-asso-ciated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine. Am J Hematol 2020; 9:194-196.
133. De Franceschi L, Costa E, Dima F, et al. Glucose-6-phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients treated with hydrox-ychloroquine/chloroquine: New case reports coming out. Eur J Intern Med 2020; 80:103.
134. Beauverd Y, Adam Y, Assouline B, et al. COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glu-cose-6-phosphate dehydrogenase deficiency. Eur J Haematol 2020; 105:357-359.
135. Saldarriaga MM, Ramirez de Oleo IE, Johnson B, et al. Retrospective Study: Association of Hydroxychloroquine Use and Hemolytic Anemia in Patients with Low Levels of Glucose-6-Phosphate Dehydrogenase (G6PD). ACR/ARHP Annu Meet 2018.
136. Mohammad S, Clowse MEB, Eudy AM, et al. Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients. Arthritis Care Res 2018; 70:481-485.

137. Schilling WHK, Bancone G, White NJ, et al. No evidence that chloroquine or hydroxychloroquine induce hem-olysis in G6PD deficiency. Blood Cells Mol Dis 2020; 85:102484.
138. Walsh EE, Frenck R, Falsey AR, et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020.
139. Mannick JB, Morris M, Hockey HP, et al. TORC1 inhib-ition enhances immune function and reduces infections in the elderly. Sci Transl Med 2018; 10:449.
140. Martel J, Wu CY, Peng HH, et al. Plant and fungal products that extend lifespan in Caenorhabditis ele-gans. Microb Cell 2020; 7:255-269.
141. Luo P, Qiu L, Liu Y, et al. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am J Trop Med Hyg 2020; 103:69-72.
142. Bramante C, Ingraham N, Murray T, et al. Observational study of metformin and risk of mortal-ity in patients hospitalized with COVID-19. medRxiv 2020.
143. Martel J, Ojcius DM, Wu CY, et al. Emerging use of senolytics and senomorphics against aging and chronic diseases. Med Res Rev 2020; 40:2114-2131.
144. Calap-Quintana P, Soriano S, Llorens JV, et al. TORC1 inhibition by rapamycin promotes antioxidant defences in a drosophila model of Friedreich's ataxia. PLoS One 2015; 10:0132376.
145. Bharath LP, Agrawal M, McCambridge G, et al. Metformin enhances autophagy and normalizes mitochondrial function to alleviate aging-associated inflammation. Cell Metab 2020; 32:44-55e6.
146. Lewinska A, Adamczyk-Grochala J, Bloniarz D, et al. AMPK-mediated senolytic and senostatic activity of quercetin surface functionalized Fe3O4 nanoparticles during oxidant-induced senescence in human fibro-blasts. Redox Biol 2020; 28:101337.
147. Kirkland JL, Tchkonia T. Senolytic drugs: from discov-ery to translation. J Intern Med 2020; 288:518-536.
148. Scheen AJ. Metformin and COVID-19: From cellular mechanisms to reduced mortality. Diabetes Metab 2020; 46:423-426.
149. Crouse A, Grimes T, Li P, et al. Metformin use is asso-ciated with reduced mortality in a diverse population with COVID-19 and diabetes. medRxiv 2020.
150. Sargiacomo C, Sotgia F, Lisanti MP, et al. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging (Albany NY). 2020; 12:6511-6517.
151. Baker JR, Donnelly LE, Barnes PJ, et al. Senotherapy: a new horizon for COPD therapy. Chest 2020; 158:562-570.
152. Willyard C. How anti-ageing drugs could boost COVID vaccines in older people. Nature 2020; 586:352-354.